Navigation Links
Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion
Date:5/2/2013

among others, the inherent uncertainty associated with financial projections; successful integration of the legacy Actavis acquisition and the ability to recognize the anticipated synergies and benefits of the legacy Actavis acquisition; the difficulty of predicting the timing and outcome of pending patent litigation and risks that an adverse outcome in such litigation could prevent us from selling products and render Actavis liable for substantial damages; risks that resolution of patent infringement litigation through settlement could result in investigations or actions by private parties or government authorities or agencies; the impact of competitive products and pricing; risks related to fluctuations in foreign currency exchange rates; periodic dependence on a small number of products for a material source of net revenue or income; variability of trade buying patterns; changes in generally accepted accounting principles; risks that the carrying values of assets may be negatively impacted by future events and circumstances; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions, if any; market acceptance of and continued demand for Actavis' products; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with governmental regulations applicable to Actavis' facilities, products and/or businesses; changes in the laws and regulations, including Medicare, Medicaid, and similar laws in foreign countries affecting, among other things, pricing and reimbursement of pharmaceutical products and the settlement of patent litigation; and such other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis' Annual Report on form 10-K for the year ended December 31, 2012.  Except as exp
'/>"/>
SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
2. Actavis, Inc. to Host First Quarter 2013 Earnings Conference Call and Webcast
3. Former Clinton Deputy Solicitor General sheds light on flaws in Federal Trade Commissions case in FTC v. Actavis Inc.
4. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
5. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
6. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
7. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
8. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
9. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
10. Watson Announces New Name -- Actavis -- for Global Operations
11. Watson and Actavis Receive FTC Second Request
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... community to review the clinical development strategy for ... on Friday, May 8, 2015. Topics will include ... planned clinical activities for AST-OPC1. ...
(Date:5/6/2015)... 2015 Delcath Systems, Inc. (NASDAQ: DCTH ... on oncology with an emphasis on the treatment of ... the three months ended March 31, 2015.  ... include: , Achieved quarterly product revenue of $0.44 ... the first quarter of 2014; , Activated a ...
(Date:5/6/2015)... Health (NYSE: CVS ) officially announced today that it will ... heavy fire damage during protests last week.  "As we ... the past week or so, our hearts turned from pain to ... CEO Larry Merlo . "Our purpose as a company is ... better way that we can fulfill that purpose than to reopen ...
Breaking Medicine Technology:Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury 2Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury 3Delcath Reports 2015 First Quarter Financial Results 2Delcath Reports 2015 First Quarter Financial Results 3Delcath Reports 2015 First Quarter Financial Results 4Delcath Reports 2015 First Quarter Financial Results 5Delcath Reports 2015 First Quarter Financial Results 6Delcath Reports 2015 First Quarter Financial Results 7Delcath Reports 2015 First Quarter Financial Results 8CVS Health Announces it Will Rebuild Baltimore CVS/pharmacy Locations 2
(Date:5/6/2015)... Texas (PRWEB) May 06, 2015 ... of the HIMSS EMR Adoption Model, the hospital ... improve patient engagement and automate processes. The leadership ... from paper-driven to electronic workflows, patient registration still ... copies of consents. With HIMSS Stage 7 attestation ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Corporate ... behalf of MEBC, an Alliance Award for excellence ... during FOCUS 2015, JDA’s annual user conference which ... retail and wholesale distribution sectors. This award recognizes ... are receiving services that advance their supply chain ...
(Date:5/6/2015)... 06, 2015 The Beryl Institute announces ... of Patient Experience Journal (PXJ), an international, open access, ... understanding and improving patient experience. The second volume of ... conversation globally, helps align the voices engaged and provides ... Published in association with The Beryl Institute, Volume 2, ...
(Date:5/6/2015)... Marketing Maven announces a ... sanitation and hygiene nonprofit by GuideStar’s Philanthropedia. , “WaterAid ... and it brings our agency great joy to work ... “The ongoing relationship between WaterAid and Marketing ... learn about and support the nonprofit as they aim ...
(Date:5/6/2015)... 06, 2015 Wolters Kluwer , ... and students, announced today that in a survey of ... use of the clinical decision support resource improves the ... of 2014, UpToDate users in more than 170 countries ... month, on average. In Germany alone, 95% of all ...
Breaking Medicine News(10 mins):Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 2Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 3Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 3Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3
... , ... Initiative to Lead Online Conversation About Health Justice in Connecticut , ... New Britain, Conn. (PRWEB) May 26, 2010 -- Health ... a movement of Connecticut residents on the issue of racial and ethnic disparities, today announced ...
... surgical procedure offers infants with severely underdeveloped hearts a ... life, in comparison to the standard surgery. ... Pediatric Heart Network studied the outcomes in 549 newborns ... left heart syndrome (HLHS). "This landmark study ...
... do the right thing, researcher says , WEDNESDAY, May 26 ... foods would open the door for manufacturers and restaurants to ... a new study finds. , A team from Harvard School ... restaurants, and found little cause for alarm. , "We found ...
... from the University of Pennsylvania have combined data from ... genetic data to shed light on the demographic history ... The study reveals not just a clearer picture ... having independent lines of evidence in the interpretation of ...
... ... for Product(s) Used in a Wide Variety of Arthroscopic Tenodesis Knee Procedures Such as: ... ... announced today it has received FDA 510k clearance for product(s) used in a wide ...
... monkey wrench into idea of individualized therapies, experts say , ... contain not one, not two, but potentially tens of thousands ... the cancer. , A sample from a lung tumor from ... in the May 27 issue of Nature . , ...
Cached Medicine News:Health News:Health Justice CT Forms Advisory Board to Raise Awareness About Health Care Quality 2Health News:Health Justice CT Forms Advisory Board to Raise Awareness About Health Care Quality 3Health News:In infant heart surgery, newer technique yields better survival in first year of life 2Health News:In infant heart surgery, newer technique yields better survival in first year of life 3Health News:Healthier Fats Replacing Trans Fats, Study Finds 2Health News:Healthier Fats Replacing Trans Fats, Study Finds 3Health News:Genetic data added to archaeology and linguistics to get picture of African population history 2Health News:Genetic data added to archaeology and linguistics to get picture of African population history 3Health News:KFx Medical Corporation Announced Today It Has Received FDA 510k Clearance for Product(s) Used in a Wide Variety of Knee Procedures 2Health News:Single Lung Tumor Contains 50,000 Mutated Genes 2
Microseal 'F' foil, seals plates for cold storage (or cycling >25l), disposable, pkg of 100...
Pkg qty: box of 2 bags pack of 25 (Pack = Zippered Bag)...
Transparent film for easy visual monitoring of samples...
... Biosystems has developed a comprehensive set ... using sequence detection systems (SDS) reagents ... and easy to follow. Many traditional ... and the thermal cycling protocol itself, ...
Medicine Products: